---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-041702"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2024-10-21T23:59:59+00:00"
generated_at: "2026-05-30T12:30:09.557138+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mira Pharma reports Ketamir-2 beats Gabapentin and Pregabalin in preclinical neuropathic pain study

## Summary
- Ketamir-2 demonstrated significantly greater efficacy than FDA-approved Gabapentin (Neurontin) and Pregabalin (Lyrica) in preclinical neuropathic pain models.
- IND application submission remains on track for end of 2024; Phase I trials expected to begin Q1 2025; Phase II by late 2025.
- Exploring government funding opportunities to support planned PTSD clinical trials.
- Additional preclinical studies focused on chemotherapy-induced and diabetic neuropathy are actively underway.

## SEC filing metadata
- accession: 0001493152-24-041702
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2024-10-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315224041702/0001493152-24-041702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315224041702/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-041702
- JSON: https://secwatch.observer/filing/0001493152-24-041702.json
- Plain text: https://secwatch.observer/filing/0001493152-24-041702.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.